MRMD MARIMED INC.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1522767 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.5%
TTM net income YoY14.4%
TTM EPS YoY20.0%
Revenue 3-yr CAGR4.8%
Net income 3-yr CAGR—
Margins
Gross margin35.4%
Operating margin-1.7%
Net margin-9.3%
FCF margin5.5%
EBITDA margin3.6%
Returns
ROE-31.6%
ROA-7.7%
ROIC (approx.)-1.8%
Asset turnover0.83x
Leverage & solvency
Liabilities / assets76.3%
Debt / equity1.95x
Current ratio0.90x
Interest coverage-0.34x
Cash quality & payout
Operating cash flow / net income-0.65x
Accruals ratio-12.7%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $159.83M | $157.71M | $148.60M | $134.01M | $121.46M |
| Cost of revenue | $101.94M | $95.10M | $82.68M | $70.05M | $55.20M |
| Gross profit | $57.88M | $62.61M | $65.92M | $63.96M | $66.26M |
| SG&A expense | $26.14M | $25.62M | $22.13M | $20.73M | $27.56M |
| Operating income | -$2.82M | $2.61M | $14.38M | $20.37M | $26.86M |
| Interest expense | $7.50M | $6.94M | $9.19M | $1.69M | $2.36M |
| Pretax income | -$10.86M | -$4.27M | -$6.60M | $19.51M | $23.82M |
| Income tax | $3.59M | $8.16M | $9.41M | $5.89M | $16.19M |
| Net income | -$14.48M | -$12.47M | -$16.03M | $13.47M | $7.22M |
| EBITDA | $5.29M | $10.52M | $19.93M | $23.80M | $28.96M |
| EPS (basic) | -0.04 | -0.03 | -0.04 | 0.04 | 0.02 |
| EPS (diluted) | -0.04 | -0.03 | -0.04 | 0.04 | 0.02 |
| Weighted avg. shares (diluted) | 390.13M | 379.15M | 363.40M | 380.29M | 372.40M |
| Balance sheet | |||||
| Cash & equivalents | $8.88M | $7.28M | $14.64M | $9.74M | $29.68M |
| Short-term investments | — | $0 | $88,000 | $123,000 | $251,000 |
| Receivables | $9.11M | $8.74M | $7.20M | $4.16M | $1.67M |
| Inventory | $36.60M | $33.49M | $25.31M | $19.48M | $9.77M |
| Current assets | $59.29M | $53.51M | $51.43M | $44.15M | $44.61M |
| PP&E, net | $89.39M | $94.17M | $89.10M | $71.64M | $62.15M |
| Goodwill | $24.00M | $15.81M | $11.99M | $8.08M | $2.07M |
| Intangibles | $17.21M | $18.64M | $17.01M | $14.20M | $162,000 |
| Total assets | $202.56M | $206.99M | $196.12M | $152.20M | $123.20M |
| Current liabilities | $59.07M | $50.01M | $30.86M | $26.49M | $27.22M |
| Long-term debt | $76.04M | $78.19M | — | — | — |
| Total debt | $76.04M | $78.19M | — | — | — |
| Total liabilities | $137.83M | $129.44M | $107.21M | $57.17M | $49.18M |
| Shareholders' equity | $51.87M | $60.30M | $70.54M | $58.82M | $37.86M |
| Net debt | $67.16M | $70.91M | — | — | — |
| Shares outstanding | 396.91M | 381.48M | 375.13M | 341.47M | 334.03M |
| Cash flow statement | |||||
| Operating cash flow | $7.70M | $6.79M | $7.91M | $7.31M | $35.85M |
| Capital expenditure | $1.17M | $11.96M | $20.13M | $12.14M | $17.87M |
| Free cash flow | $6.53M | -$5.17M | -$12.22M | -$4.83M | $17.98M |
| Investing cash flow | -$1.38M | -$17.13M | -$25.98M | -$26.24M | -$16.62M |
| Financing cash flow | -$4.71M | $2.98M | $22.98M | -$1.01M | $7.45M |
| Depreciation & amortization | $8.11M | $7.91M | $5.55M | $3.43M | $2.10M |
| Stock-based compensation | $1.86M | $1.05M | $1.02M | $6.34M | — |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.